Following the lead of multiple branded drug makers this year, generics outfit Hikma is pledging $1 billion to bolster its U.S. manufacturing and R&D.

Hikma Pharmaceuticals USA has started work on a $1 billion investment that includes an expansion of its West Side facilities.

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines By Hikma Pharmaceuticals USA Inc.

Bayt Al Khair revealed that its total expenditure for April 2025 amounted to Dhs10,504,184, bringing the cumulative spending for the first four months of 2025 to Dhs85,954,842. Humanitarian support ...

The event, which marks the World Day for Cultural Diversity for Dialogue and Development, commemorated globally on May 21 each year, was organised in collaboration with the UNESCO Regional Office for ...

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday unveiled new medium-term guidance forecasting high single-digit revenue and operating profit growth in the three years to 2027. The London ...

Hikma reiterates full year guidance following good start to the year Hikma reiterates full year guidance following good start to the year London, 24 April 2025 – Hikma Pharmaceuticals PLC (Hikma, ...

Hikma acquires Novugen’s FDA-approved ANDA for generic Mekinist Trametinib is an orally administered kinase inhibitor medication used to treat certain cancers.

Hikma buys rights to FDA-approved cancer treatment trametinib, a generic version of Novartis' (NVS) Mekinist, with 180 days of U.S. market exclusivity. Read more here.

The president of NGO Bayt Al Hikma speaks to Magharebia about her group's mission and the most important issues facing Moroccan society. Bayt Al Hikma is a non-governmental organisation founded in ...